Defer the Crysvita Infusion Until Fever Status is Clarified and Symptoms Resolve
The infusion center should NOT proceed with the Crysvita infusion today until the child's current temperature is measured and the acute illness is evaluated. If fever is present or the child appears acutely ill, the infusion should be postponed until symptoms resolve.
Clinical Reasoning
Why Temperature Assessment is Critical
The parent reports fever as one of the symptoms, but the current fever status is unknown. This is a critical gap that must be addressed before proceeding:
- Pyrexia (fever) is the most common adverse event with Crysvita, occurring in approximately 75% of pediatric patients in clinical trials 1, 2
- Administering Crysvita during an active febrile illness could:
- Mask or confound the source of fever (drug-related vs. infection-related)
- Potentially worsen the child's clinical status
- Make it impossible to distinguish between treatment-emergent adverse events and progression of the underlying illness
Safety Profile Considerations
While Crysvita has a generally favorable safety profile 1, 3:
- Most treatment-emergent adverse events are mild to moderate 3, 4
- The drug is well-tolerated with rare serious adverse events 2, 5
- However, cough is also a common adverse reaction (>25% in pediatric patients) 1
The overlap between the child's current symptoms (fever, cough, headache) and known Crysvita adverse events creates a clinical dilemma that makes it unsafe to proceed without first establishing baseline status.
Recommended Action Algorithm
Step 1: Immediate Assessment (Before Infusion Decision)
- Measure temperature now at the infusion center
- Perform brief clinical assessment for:
- Respiratory distress (increased respiratory rate, retractions, grunting)
- Hydration status
- Level of alertness/activity
- Severity of cough and congestion
Step 2: Decision Tree Based on Findings
If temperature ≥38.5°C (101.3°F) OR child appears acutely ill:
- DEFER the infusion
- Advise parent to seek medical evaluation for the acute illness
- Reschedule infusion for after symptom resolution (typically 24-48 hours after fever resolves without antipyretics)
If temperature <38.5°C AND child appears well (mild URI symptoms only):
- Consider proceeding with infusion
- Ensure close monitoring during and after infusion
- Document baseline symptoms clearly to distinguish from potential treatment-emergent adverse events
- Provide clear return precautions to parents
If unable to assess temperature or clinical status adequately:
- DEFER the infusion (err on the side of caution)
Key Pitfalls to Avoid
Never proceed with an infusion when fever status is unknown - this creates an unsafe situation where you cannot properly monitor for adverse events
Do not assume "just a cold" is benign - while the symptoms may represent a simple viral URI, children with chronic conditions receiving biologic therapy warrant more conservative management
Document everything - if you do proceed after assessment, clearly document the child's baseline symptoms, vital signs, and clinical appearance to enable proper adverse event monitoring
Consider the 2-week dosing interval - Crysvita is given every 2 weeks 1, 3. A delay of 2-3 days for illness resolution will not significantly impact therapeutic efficacy and is far safer than proceeding with an infusion during acute illness
Practical Guidance
The infusion center should:
- Take the child's temperature immediately
- If fever is present or child appears ill: reschedule for 24-48 hours after symptom resolution
- If afebrile and well-appearing with only mild symptoms: use clinical judgment but lean toward deferral given unknown fever history
- Contact the prescribing physician if there are questions about proceeding
The risk-benefit analysis strongly favors deferral when acute illness is present or suspected, as the consequences of administering Crysvita during active infection (diagnostic confusion, potential worsening of symptoms) outweigh the minimal delay in therapy.